Li-Fraumeni syndrome (LFS) is a highly penetrant cancer predisposition syndrome caused by germline TP53 mutations. Genetic testing is not routinely offered in asymptomatic children at risk of the condition as the benefits are debatable and the attitudes of families and health care professionals (HCPs) may vary. This review assessed the attitudes of families and HCPs towards offering genetic testing to children for LFS, with a focus on perceived advantages and disadvantages and involvement of children in the decision-making process. We searched three key databases (Medline, PsycINFO and EMBASE) to identify quantitative and qualitative studies. We screened 729 articles identifying eight studies for detailed review. Most parents perceived TP53 genetic testing to be beneficial in childhood, despite previous lack of surveillance guidelines.
| INTRODUCTION
Li-Fraumeni syndrome (LFS) is a rare, highly penetrant, autosomal dominantly inherited cancer syndrome, characterised by a high risk of developing various types of cancer from early childhood into adulthood caused by mutations in the TP53 gene. 1 Originally discovered through clinical observations and epidemiological studies, LFS has an estimated birth prevalence of one in 5000. 2 LFS affected individuals have up to a 90% lifetime risk of developing (multiple) primary cancers of various types. About 20% to 25% of LFS affected individuals will develop cancer by age 20 3 compared with 0.2% in the general population. 4 The most commonly occurring malignancy in LFS is pre-menopausal breast cancer. 3 Other cancers associated with this syndrome include soft tissue sarcomas, osteosarcomas, acute leukaemia, adrenocortical tumours, brain tumours and a variety of childhood and adult-onset tumours. 5 Up to one-third (15%-35%) of cancer survivors with LFS will develop multiple primary cancers over their lifetime. [6] [7] [8] LFS predisposes affected individuals to radiation-induced malignancies. 9, 10 Testing of at-risk children for an identified TP53 mutation has been considered controversial because of the previous lack of proven medical benefit of screening, concern about informed consent and potential stigmatisation and discrimination towards the child.
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Genetic testing guidelines recommend that in situations where there is no medical benefit to the child in the immediate future, extreme caution is advised and the young person's best interest must be paramount. 12, 13 However, due to emerging screening protocols showing potential efficacy through enhanced screening, testing of at-risk children is becoming less controversial in sites where access to wholebody magnetic resonance imaging (WBMRI) is available. 14, 15 Recent studies have suggested improved medical and psychological outcomes for TP53 mutation carrier undergoing rigorous screening. 14, 16 The Toronto protocol, which incorporates WBMRI among other modalities, including brain MRI and quarterly abdominal ultrasound, was associated with improved survival. 14 However, in part because of the rarity of LFS, definitive evidence of the benefits of screening is lacking. A recent meta-analysis showed that WBMRI was effective in detecting cancers in both children and adults. 15 The American Association for Cancer Research (AACR) recently recommended adoption of the Toronto Protocol in children with a pathogenic LFS variant or a clinical diagnosis of LFS. 17 Despite such recommendations, no universally accepted approach to management exists and screening recommendations may vary between countries, 17 with
Australia currently offering screening to children on an individual basis tailored to their family history. 18 Independent to a medical benefit, genetic testing may be considered if there is a psychological or social benefit to the child or their family. 19 Genetic counselling can provide comprehensive information about a child's genetic condition and status, facilitate informed decision-making and help families plan for the future. 20 A negative genetic test result can provide relief for children and their families. 21 Conversely, a positive test result may impact self-esteem when the child's understanding of illness and disease is limited. 22 A key tenet of genetic testing is informed consent. Testing children can be especially complex as their parent or legal guardian must make medical decisions and provide consent. Generally, we expect that parents are in the unique position to determine what is in the best interest of their child. 23 However, achieving fully informed consent may be challenging if parents do not fully comprehend the longterm impact and implications of genetic testing for their child. 24, 25 Parents may also have a personal or familial motivation for requesting genetic testing, which needs to be balanced against the best interests of the child. [26] [27] [28] [29] The child's future autonomy and participation in decision-making may be diminished if parents are the sole decision makers. 27, 28 As children mature, they are usually involved in the health care decision-making process. Competent decision-making relies on an individual having the capacity to understand and synthesise information. 28 Children have varying abilities to understand the aims and process of genetic testing and the potential long-term impact of test results, which may preclude them from decision making. However, children as young as seven are able to participate in decisions and by age 12 some children will have sufficient capacity to evaluate the risks and benefits of tests. 28, 30 It is generally accepted that "as soon as children are able to communicate and participate in decisions that affect them, they should be encouraged to participate in all aspects of the decision-making process" p. 289.
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Timing of genetic testing during childhood is likely to be important. The receipt of genetic test results during puberty may impact the important developmental process of identity formation. 30 Children and adolescents may lack the ability to comprehend the potential long-term impact of genetic testing decisions on their lives. 28 The older a child becomes, the more likely they are to grasp the intellectual concepts and have the skills needed to make these decisions. parents who may experience "transmission guilt," 30, 35 and their siblings who have not inherited the familial susceptibility who may experience "survivor guilt." 30, 35 Conversely, children may derive significant benefit by relieving uncertainty, by either being certain about their risk and developing coping strategies, or experiencing the relief of receiving a negative result. 28 As evidence of the medical utility of TP53 genetic testing mounts, it is important to examine clinicians' opinions about ordering testing.
A balance must be reached between managing parental requests for TP53 genetic testing and maintaining the best interests of the child being tested. As public acceptance of genetic testing increases and the evidence of the medical utility of screening mounts, it is important to understand and review the available literature on who facilitates and orders TP53 testing in children.
This systematic review will provide key insights into attitudes of parents, children and health care professionals (HCPs) to better guide the suitability of LFS testing in children. We aimed to answer the following key questions: 
| Inclusion and exclusion criteria
Both quantitative and qualitative studies were eligible for inclusion if area and the few studies eligible for inclusion, the "grey literature"
(work of potential high quality that was published outside peerreviewed sources) was also searched. Opinion pieces and commentaries were excluded.
| Data extraction and quality assessment
We extracted the data and assessed the quality of the available evidence using the Mixed Methods Appraisal Tool (MMAT), 36, 37 which allows simultaneous assessment of both qualitative and quantitative studies. Two reviewers (MW and KMT) independently screened titles and abstracts and quality appraisal, and any disagreements were discussed until consensus was reached. Given the wide-reaching approach of this review, quality score was not used to exclude studies, but instead to highlight areas for further research. The results of the search strategy are shown in Figure 1 .
| RESULTS
Following de-duplication, a total of 729 abstracts were identified and 23 full-text articles were extracted for in-depth review. Six studies met all inclusion criteria. Two additional eligible articles were identified after reviewing the references of the six included articles, culminating in a total of eight articles meeting the inclusion criteria. The eight articles included in this review examined the views of parents (n = 115), children (n = 12), HCPs and families (n = 7 descriptive case studies). The articles' study characteristics and main findings are summarised in Table 1 .
| MAIN OUTCOMES
Six studies assessed attitudes of parents towards testing children 11, [38] [39] [40] [41] [42] ; two retrospective cross-sectional studies assessed Article identified from reference list review (n=2). personal attitudes towards their own testing as children and its effects 41, 43 ; two studies reported on the HCPs' experiences related to TP53 testing in children 39, 44 ; and six studies examined the involvement of children in the decision-making process. 11, [39] [40] [41] [42] [43] The studies were conducted in the United States (n = 4), France (n = 2) and the United Kingdom (n = 2).
Three studies reported that overall acceptance of testing was high, 38, 40, 42 with one study reporting a slight increased uptake when results were required to inform management of an affected child. 38 Patenaude et al. 42 reported that 42% of parents would test regardless of the benefits as opposed to a higher proportion of parents testing if there was a medical benefit to testing their child (97%). Parents felt they had a right to know even if the clinician disagreed with them. Parents felt a responsibility to test their child as they perceived it was in their child's best interest. 38 Knowing that their child did not have a predisposition would mean de-medicalisation of their child and increased uptake of normal activities. 11, 38, 42 Parents felt it would also provide benefits to siblings and inform family planning. 38 Predictive testing in childhood allowed the child time to adjust and become better equipped to make management decisions when recommended (eg, breast screening). Parents indicated that possible discrimination by future employers and concern of insurance companies accessing medical information was also a deterrent. 11 Eighty percent (n = 4) of respondents ranked insurance discrimination as "very important." 40 A proportion of parents were concerned about informing their paediatrician about genetic test results because of concerns of confidentiality. 42 However, insurance concerns would not ultimately alter their decision to proceed with testing.
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| Loss of autonomy
Three studies identified the child's diminished autonomy if testing was conducted in childhood. 11, 38, 42 A minority of parents would not proceed with mutation testing as they wanted to allow their children to make this decision autonomously as an adult, 11, 38 and were reluctant to test healthy children. 42 
| Negative emotional impact
Four studies identified a potential negative emotional impact as a deterrent, with parents feeling they would become depressed if their healthy child was diagnosed with LFS. 38, [40] [41] [42] Although family planning was cited as a reason to test, one case study identified that knowing about the syndrome made the parents feel "cursed" and subsequently they did not want more children. 41 The minority of parents felt that the child knowing their mutation status would be burdensome and too emotionally challenging for them 38, 40 and they would not want their child living in fear if tested positive. 42 They also expressed concern of a loss of innocence for their child if tested positive. 38 Parents reported that knowledge of their child's positive mutation status would result in increased parental cancer-related anxiety that would negatively impact their parenting style. Parents were also concerned that their child's future aspirations would also be negatively affected.
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"The biggest thing going through my mind was, if she comes back positive, then we're going to treat her very different, like a child with a disability and we're going to change her upbringing. She's not going to be this carefree little girl." (Father, predictive testing, p. 291).
One study found 51% (n = 24) of parents felt that they would be likely to give their children more attention if they were positive, with the majority feeling they would monitor their child more carefully. 42 Children's attitudes:
Two studies assessed children's attitudes, 41, 43 with all children believing that genetic testing should be offered for children. 43 Perceived advantages:
Emotional impact:
Children identified knowing their status, regardless of result, reduced anxiety and increased their sense of power. 43 Three participants mentioned potential benefits to family members and future generations as additional reasons to test. One child was "relieved" when a gene mutation was identified in him as the family history then made logical sense and seemed more manageable. 41 Children indicated that the possibilities of negative emotions were outweighed by the potential benefits to themselves and their families. 43 Children who underwent genetic testing stated knowledge of their results had little to no impact on their family relationships; however, a mutation-negative sibling experienced survivor guilt. 43 
Medical benefit:
Greater understanding of their risk profile was cited as the main advantage of genetic testing, along with allowing for disease prevention effort and the opportunity to make healthy lifestyle changes. 
Perceived disadvantages:
Negative emotional impact:
Anticipated worry or negative emotions associated with a positive test result was cited as a deterrent, however, this was offset by the benefits and likely related to an individual's tendency to worry. 41, 43 Two-thirds (n = 7/12) of children reported that negative emotions associated with a positive genetic test result would be a potential disadvantage of testing, with 42% (n = 5/11) of children tested reported that they did not fully comprehend the significance of testing until after the results and management was discussed. 43 One child who previously tested positive reported that the results altered their career choice, 43 however, it was unclear if this was advantageous or disadvantageous.
Physical impact:
Children reported the physical discomfort of a blood test itself to be a disadvantage. 43 Clinician's attitudes:
Two studies assessed the attitudes of HCPs (Geneticists and Genetic Counsellors) responsible for offering germline testing for LFS in children. 39, 44 Clinicians felt under "extreme" pressure to offer testing in children even for a condition where no screening recommendations were available. 39 For the minority of clinicians who did offer predictive testing, it was highly recommended that there be a minimum of three counselling sessions and access be limited on a case-bycase basis. 39 Fresneau et al. 44 found that the majority of clinicians adhered to French guidelines and did not offer genetic testing to children because of no proven medical benefit, concern of creating more anxiety with a positive result (n = 5) and diminished child autonomy.
However, for those who did, family history, severity of cancers in the family, possibility of targeted surveillance programmes, alleviation of parent anxiety and allowing for future planning were positive factors influencing their decision.
Decision-making process and involvement of children:
Seven studies reported on involvement of children in the decision-making process. 11, [39] [40] [41] [42] [43] [44] The majority of parents would involve their child in the decision-making process but this was highly dependent on the child's age and level of participation.
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Parents attitudes:
Parents felt that a child's involvement was age dependent. 11, 40, 42 It was generally accepted that children between 10 and 15 years could effectively participate in the discussion, although children as young as 9 years old were involved in the process quite successfully. 11, 39 Although most parents thought that children should be involved, one participant strongly disagreed with this view. 40 Appropriate genetic counselling was appreciated with a post-test debriefing session ideal and not considered over-burdensome. 39 Patenaude et al. 42 reported that all parents agreed that children should be told the outcome of the testing but ages varied, with a third wanting to wait until after the child turned 18 years. One retrospective case study identified conflict between parents and relatives who differed in their views on whether or not to tell children, and resulted in conflict within the family. 41 Children's attitudes:
In one study, all children (n = 12) indicated that children should be involved in decision-making but commented that parents could unilaterally decide under certain circumstances. Of the eight children tested, all indicated that they had adequate involvement in the decision-making process, those not involved reported this was appropriate given their young age at testing. 43 
HCPs' attitudes:
Two studies commented on the need to include children in the decision-making process when age appropriate, suggesting the age range of 12 to 18 years 39, 44 and highlighted the dilemma experienced by clinicians in balancing the parents' requests with what they believed was in the best interests of the child. Despite reservations, no adverse consequences were noted after 12 months. 39 
| DISCUSSION
This systematic review provides a perspective on parents', children's and HCPs' attitudes towards childhood genetic testing for LFS. However, this area of research remains in its infancy, as evident by the few eligible studies found across only a few countries. In this review, parents overall expressed positive attitudes towards childhood genetic testing for LFS, with perceived benefits mentioned including reduced anxiety and de-medicalisation of mutation-negative children. Some perceived disadvantages were identified, such as increased anxiety if a child tests positive, decreased insurance and employment potential and negative impacts on family functioning. However, the majority of children tested self-reported the impact of genetic testing to be minimal. Although findings were limited to two studies, HCPs were inclined not to order the testing due to the lack of proven medical benefit in childhood at the time of the study but felt pressure from families to prescribe testing. Parents, children and HCPs were overall inclined to involve children in the decision-making process, but this was age dependent.
The results of this review indicate parents' positive attitudes and eagerness for the availability of TP53 genetic testing in childhood, despite lacking evidence at the time of the respective studies. These attitudes are challenged by best practice guidelines, which stipulate that childhood testing should only be undertaken when there is a proven medical benefit for the child. 30 Even prior to strong evidence of medical utility, parents remained optimistic and viewed testing as the first step in identifying appropriate medical surveillance. The results indicated that parents gained benefit in the form of reduced anxiety (regardless of the outcome), de-medicalisation of unaffected children and clarity of cancer risk for siblings and subsequent generations. Our review showed that a positive TP53 test result could also have positive effects resulting in alleviating doubt, a longer time to adapt to and prepare for the future and the opportunity to consider risk reduction surgery such as risk-reducing mastectomy in women. 41, 43 This is similar to previous studies regarding predictive testing, which found obtaining certainty of a diagnosis was of significant psychological benefit. [45] [46] [47] This attitude is reflected in a previous
Familial Adenomatous Polyposis study that found that some children worried less and showed a decrease in situational distress after testing negative due to lower perceived risk of getting cancer. 21 Taking into consideration of family's pre-existing risks of psychological distress, genetic counselling is essential to anticipate these potential risks and to provide support appropriately, with results showing families were eager to engage in this process.
Parents frequently viewed genetic testing for LFS as a potential first step towards a screening programme. 39, 44 The AACR now recommends adherence to the Toronto Protocol for any individuals carrying a pathogenic TP53 variant and individuals fitting the "classic" clinical definition of LFS, without a pathogenic variant. 17 A recent meta-analysis of 13 prospective cohorts assessed the detection rates of asymptomatic cancers using WBMRI identified through the LiFraumeni Exploration Research Consortium. 15 Of the 578 participants, 42 cancers were identified in 39 individuals, 12 of which were diagnosed in individuals 17 years and under. No new primary cancer was metastatic at detection. Almost one in three participants was found to have a false positive requiring future investigation leading to potential distress, medical morbidity and cost. 15 Despite this, a recent study on the acceptability of WBMRI in the LFS population observed that screening reduced anxiety and may provide psychological benefit for participants. 16 One of the main perceived deterrents cited by parents was insurance implications and fear of decreased employment opportunities. 38, 42 Due to the rarity of LFS no studies have captured the effect of this syndrome on insurance and employment; however, Huntington's disease and Li-Fraumeni have been compared in the literature because of the potential to develop the diseases in adolescents. 39 Taylor et al. 48 reported some respondents, most probably those where recommended that employers should not be permitted to collect or use genetic information regarding employees, or potential employees, except when it is specifically related to health and safety. 48 The finding also noted that respondent expressed equal concern about both employers and insurers having legally-sanctioned access to genetic information. Such attitudes are consistent with those of the broader Australian community. 49 Despite favourable attitudes towards testing, it is important for clinicians to monitor levels of distress in parents and children, as this distress may contribute to children's cancer-related worries and could profit from psychosocial support. As demonstrated in a previous case study, mutation-positive families withdrew from the medical and social communities because of the impact of LFS on their lives. 41 Also, children and young adults reported that they did not fully comprehend the significance of the result until after testing was complete. Further psychological support may be warranted for these families and regular follow-up from genetic services is encouraged. 43 The concept of testing a child only when it is medically relevant for them is to preserve and protect their autonomy and their right to decline genetic testing. 50 The uptake of TP53 genetic testing was lower in adults when compared to parent's uptake of testing for their children.
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This may imply that a proportion of children would not have consented to testing if testing was delayed until adulthood. For some children, undergoing genetic testing during adolescence may result in psychosocial challenges that could have been avoided if the child had learned his or her genetic status at a younger age. It would be reasonable for parents to defer genetic testing until their child is old enough to have active participation in the decision. This notion is supported in this review with most participants believing that children should be involved in decision making when age appropriate (generally from age 10). 43 It is therefore important to involve children as well as their guardians in counselling and information-giving sessions.
Because parents are usually best qualified to make decisions for their family, communication and collaboration with the child's parents is essential to ensure the best outcomes when considering genetic testing in childhood.
The majority of parents would involve their children in the decision-making process to an extent, and viewed the age of 11 to 17 as acceptable. 38 All children tested concurred that children should be involved in the process, with the majority of those testing felt they had adequate involvement. 43 If a child is young, delaying testing until the child can actively participate shows respect for the developing capacities of the maturing minor. 51 However, some children ultimately felt parents should make the decision. 43 A recent study of 46 parents of children at risk of LFS acknowledged adolescent should take more responsibility of their health care decisions and knowledge of their risk may moderate risky health behaviours. 52 Conversely, parents worried that testing during adolescents, an already emotional difficult time, may heighten negative emotions associated with testing. 52 Despite parental concerns, the majority of adolescents tested did not report being negative affected by the testing process. 43 Although limited to one study, the majority of French clinicians would not routinely order TP53 genetic testing in childhood. 44 The 
| Limitations
Given the lack of literature in this area, it was necessary to assess all available evidence, regardless of quality, to explore attitudes and highlight areas for future research. The review contained studies of variable quality, participant groups, size and methodologies which may affect the robustness of the review. Despite use of broad search terms, only a small proportion of the studies were eligible, which may be reflective of the rarity of this condition. This search was limited to English language papers, which meant that potentially important studies were excluded. Three of the eight studies are more than 10 years old and may no longer accurately reflect parental views on disadvantages such as insurance discrimination. 39, 41, 42 No Australian-based studies were available, so the insurance concerns among Australian parents considering predictive testing of their children may not be accurately reflected.
| Future directions
This review underscores the need for more research to facilitate the understanding of parents', children's and HCPs' attitudes towards TP53 mutation testing. The positive attitudes observed in this review suggest a likely increasing demand for Li-Fraumeni testing in children.
However, there is limited literature of the attitudes of clinicians facilitating testing. Further research on clinicians' attitudes may lead to meaningful comparisons between responses of parents and providers.
Although parents believe that testing their children is an essential first step to identifying effective screening modalities, more research is needed in the efficacy of screening and its impact on childhood morbidity and mortality. Despite hesitations of testing children, the majority of children tested reported no negative impact on their outlook.
However, the long-term psychosocial impact remains unclear. Longterm prospective studies may elucidate this further. 
| CONCLUSION

